IL-23/CGRP bispecific antibody (Lilly)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameIL-23/CGRP bispecific antibody (Lilly)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionCalcitonin gene-related peptide antagonistsInterleukin-23 inhibitors

TargetsInterleukin-23Calcitonin gene-related peptide

Therapy Area/IndicationsAutoimmune Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesEli Lilly And Company

China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And Company

Inactive CompaniesN/A

Active IndicationsAutoimmune Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A